Losartan Therapy in Pulmonary Hypertension
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of...
Brief Summary
Official Title: “Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension”
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: nifedipine, losartan
- I: nifedipine 30 mg/d II: losartan 50 mg/d
- Drug: losartan
- II: losartan
- Drug: Nifedipine, losartan
- I: nifedipine II: losartan
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: I, II
- I: nifedipine II: losartan
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean pulmonary artery pressure of > 26mmHg)
Exclusion Criteria:
- acute infectious or inflammatory disease,
- exacerbation of chronic obstructive pulmonary disease,
- malignancy,
- acute coronary syndrome in the last 4 weeks,
- uncontrolled arrhythmia and hypertension,
- decompensated heart failure,
- acute pulmonary emboli,
- thrombus in a lower extremity,
- oxygen saturation below 85% at rest,
- failure to cooperate with CPET
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Baskent University Other
Overall Clinical Trial Officials and Contacts
Serife Savas Bozbas, MD Principal Investigator Baskent University Faculty of Medicine, Department of Pulmonary Disease
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00519870
Study ID Number: KA04/127
ClinicalTrials.gov Identifier: NCT00519870
Health Authority: Turkey: Ministry of Health
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00519870
